Steward Partners Investment Advisory’s Artiva Biotherapeutics ARTV Stock Holding History

Steward Partners Investment Advisory’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.85K	Buy	+500	New	+$4.55K	﹤0.01%	3990

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Steward Partners Investment Advisory's ARTV Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 500 shares worth $4.85K. The stake represents ﹤0.01% of the portfolio and ranks #3990 among its holdings.

65 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Steward Partners Investment Advisory held 500 shares of Artiva Biotherapeutics worth $4.85K as of Q2 2026.
Artiva Biotherapeutics was a new Steward Partners Investment Advisory position in Q2 2026.
Artiva Biotherapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3990 holding.
65 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.